Introduction {#s1}
============

Non-tuberculous mycobacteria (NTM) are gram positive, acid-fast organisms found naturally in soil or water ([@B1]--[@B3]). Historically, NTM were identified alongside the identification of *Mycobacteria tuberculosis*, but were not known to cause human disease until the 1950\'s ([@B4]). Although NTM are extensively spread in the environment, occasionally they cause pulmonary infection. This fact suggests that intrinsic susceptibility in some people plays an important role in onset of NTM disease ([@B1]). Bronchiectasis, abnormal alpha-1 antitrypsin gene alleles, immunosuppressive states, lung aging and chronic obstructive pulmonary disease (COPD) are some of known risk factors for NTM diseases ([@B5], [@B6]).

COPD is one of the most common pulmonary diseases globally. The prevalence of COPD among adults in the US represents between 5.1 and 6.2% of the overall adult population ([@B3], [@B7]). In comparison, the prevalence of cystic fibrosis in the US is estimated to be 30,000 (or 0.01% of the US population) ([@B8]). In the US Veteran population, prevalence of COPD is considered higher than the general population. Administrative data from the Veterans Affairs network reported a COPD prevalence of 8.8% among all veterans and a study evaluating airflow limitation among veterans suggested a COPD prevalence of 33--43% ([@B9], [@B10]). This higher incidence may be a reflection of the veterans higher rates of tobacco use compared to non-veteran civilians, in part because of its use as a coping mechanism to relieve stress, boost energy, suppress appetite and withdrawal symptoms ([@B11], [@B12]).

There are limited data on the epidemiology of NTM infections on a national level. Even less is known about the prevalence of NTM among the patients with COPD, particularly in veterans\' population. The purpose of the present study was to evaluate the incidence and prevalence rates, geographic distribution, and mortality of pulmonary NTM infections among veterans with COPD in the US by conducting a two-phase study. First, a hypothesis was tested on a significant increasing in the incidence and prevalence rates of NTM among veterans with COPD in the last 15 years. We also hypothesized that geographic distribution of NTM infections is not equal in the US. Second, we hypothesized that NTM is an independent risk factor for mortality in veterans with COPD and analysis was undertaken to evaluate the association between NTM infection and mortality in veterans with COPD.

Methods {#s2}
=======

Study design
------------

We performed a retrospective, cross-sectional study using the Veterans Affairs Informatics and Computer Infrastructure (VINCI). VINCI is a mega-clinical data network generated from more than 152 VA medical centers across the US and territories, serving more than 8 million veterans. This database contains inpatient and outpatient claims data dating back to October 1999, combined with patient data from electronic medical records ([@B13]). The study was reviewed and accepted by the Miami Veterans Affairs Healthcare System ethics committee as reflected in the approval number 574.01. Consent was waived due to the retrospective nature of the study.

Study period and population
---------------------------

We used information from medical records for patients seen at any Veterans Affairs Hospital in the US from 2001 to 2015. Queries were performed for patients seen with a diagnosis of COPD, based on the International Classification of Diseases, 9th (ICD-9) and 10th (ICD-10) revisions. Subjects with multiple encounters were condensed, and duplicates were removed. Data prior to the year 2001 was excluded due to inconsistency in data collection for COPD at VA Hospitals.

Criteria and definitions
------------------------

The subset of COPD patients (ICD-9: 491, ICD-10: J.44.0, J.44.1, J.44.9) were subsequently queried for patients with superimposed pulmonary NTM infections (ICD-9: 031, ICD-10: A31.9), defined as being diagnosed with NTM up to within the same calendar year of the diagnosis of COPD. The presence of NTM and COPD were defined based on diagnostic claims for each veteran if they occurred on ≥2 separate occasions ≥30 days apart. The annual prevalence was calculated as the number of existing NTM cases divided by total number of COPD cases in each year of study (2001--2015) multiplied by 100,000. Incidence rates were defined as the number of new NTM diagnosis for that time period per 100,000 COPD patients. A case of NTM was defined as a new diagnosis if there were no prior diagnostic claims for NTM for that patient. Poisson regression adjusted by age was used to measure each year\'s trend of the prevalence and incidence of COPD and NTM.

Geographic distribution
-----------------------

A heat map graph was generated to provide data on the density of distribution of NTM infections across the different states. The data grid was based on the geographical coordinates of each subject\'s city of residence and was generated using the Kriging method ([@B14]). Geographic coordinates for the continental United States were included. Data from Puerto Rico, Alaska and Hawaii were excluded in the heat map to achieve better accuracy for the mainland. The filled contour map was generated using the medium smoothing method.

Mortality analysis
------------------

For patients with NTM to qualify for this part of analysis, NTM infection must have been diagnosed at least 1 year after the COPD diagnosis and not any sooner as shown in Figure [S1](#SM1){ref-type="supplementary-material"}. To ensure that the first entry coding for COPD actually reflects the diagnosis being made rather than transition to an electronic medical record for a previously diagnosed patient, we excluded patients who did not have another diagnosis entered in their record at least 3 years before the first diagnosis of COPD. Additionally, only those patients after 1/1/1999 were included in the mortality analysis.

We collected age, gender, first date of COPD diagnosis, first date of NTM diagnosis and first date of comorbidities including lung cancer, end stage renal disease (ESRD), congestive heart failure (CHF), liver disease, pneumonia, aspergillosis, AIDS, diabetes mellitus, coronary artery disease (CAD), psychiatric disease, tobacco use, immune disorders, cancer, depression, atherosclerosis, organ transplant, cystic fibrosis, hypertension, bronchiectasis, interstitial lung disease (ILD), pectus excavatum, connective tissue disease and tuberculosis. We defined the date of diagnosis as the date of the first diagnostic claim for that condition. The ICD-9 and ICD-10 codes related to above comorbidities are listed in Table [S1](#SM1){ref-type="supplementary-material"}.

Statistical analysis
--------------------

We performed all analysis using Stata statistical software. A *P*-value \< 0.05 was considered statistically significant. The principal outcome was the relative hazard for death due to NTM infection, determined using time dependent multivariable proportional hazards regression with inception at the time a diagnosis for COPD was entered into the medical record. The relative risk for death was permitted to vary by day, changing as other diagnosis, including that of NTM. Diagnoses were treated as persistent over time and with unchanging contribution to the hazard term once diagnosed. Follow-up was censored at the date of last known contact with a Department of Veterans Affairs clinic or hospital for patients not documented to have died.

Results {#s3}
=======

From a total of 2,050,355 veterans with COPD, 4,676 (0.23%) met our criteria for concurrent pulmonary NTM.

Age at diagnosis
----------------

The age at diagnosis of Pulmonary NTM shows a consistent pattern over time Table [S2](#SM1){ref-type="supplementary-material"}. The age at diagnosis ranged from 66.1 in 2001 to 68.5 years old in 2011, and there was no statistically significant difference in the age of diagnosis over the study period (*p* = 0.25).

Prevalence of NTM infection in veterans with COPD
-------------------------------------------------

Over the study period, there was a statistically significant change in the prevalence rate of NTM infections in veterans with COPD over time (*p* \< 0.0001). The prevalence rate rose from 93.1 in 100,000 in 2001 to 277.6 in 100,000 in 2015 with a sharp rise occurring around 2012 (157.0 in 100,000 in 2012, and 182.8 in 100,000 in 2013). The percentage change in prevalence rate was 81.5% over 2011--2015, compared to a 30.4% change in 2001--2005 Table [S3](#SM1){ref-type="supplementary-material"}.

Geographic distribution per period prevalence of NTM
----------------------------------------------------

Geographic analysis showed that coastal areas of the US were highly affected and hotspots appeared near Lake Michigan, Louisiana, Florida, and the Southwestern United States. Puerto Rico, Florida, and District of Colombia represented the states with the highest period prevalence (370 in 100,000, 351 in 100,000, and 309 in 100,000, respectively) in the nation. The heat map (Figure [1](#F1){ref-type="fig"}) demonstrates the period prevalence of NTM in COPD patients in the US in 2001--2015.

![Period prevalence of NTM in COPD patients across the Continental US.](fmed-05-00311-g0001){#F1}

Incidence of NTM infection in veterans with COPD
------------------------------------------------

During 2001 to 2015, there was a sharp increase in the number of new cases over years. The incidence rate in 2001 was 34.2 in 100,000 COPD patients and was steady until 2012. After 2012, there was an increase in the incidence rate, until the end of 2015, which had an incidence rate of 70.3 in 100,000 (Figure [2](#F2){ref-type="fig"}). Divided into 5 years intervals, the percentage change in incidence rate was 151.1% increase over 2011--2015, compared to a 27.5% decrease in 2001--2005 Table [S3](#SM1){ref-type="supplementary-material"}. Overall, there was a statistically significant change in the incidence rate over time (*p* = 0.035).

![Prevalence and incidence rates of NTM among veterans with COPD.](fmed-05-00311-g0002){#F2}

Gender variation in incidence of NTM
------------------------------------

Overall, the incidence of NTM in COPD in both genders increased over time (*p* = 0.039 for males, *p* = 0.008 for females). The NTM incidence rate in males went from 33.5 in 2001 to 67.5 in 100,000 in 2015, a percent change of 101.5%. Similar to the overall incidence trend, the incidence rate in males rose sharply after 2012 (Figure [3](#F3){ref-type="fig"}).

![Incidence rates of NTM among veterans with COPD over time stratified by gender.](fmed-05-00311-g0003){#F3}

While the percentage change in NTM incidence rate in females was greater than males (0.7 per 100,000 in 2001 to 2.8% in 2015, a percentage change of 300%) the absolute change in incidence rate was more modest (an increase of 2.1 cases in 100,000 in females compared to an increase of 34.0 cases in 100,000 in males).

Analysis of the proportion of incident cases represented by different genders shows a modest but steady increase in proportion of female cases over the 2001--2015 period (*p* = 0.052), representing 4% of all new cases by the year 2015 (Figure [4](#F4){ref-type="fig"}).

![Proportion of new NTM cases based on gender among veterans with COPD.](fmed-05-00311-g0004){#F4}

Mortality risk and presence of NTM infection
--------------------------------------------

This analysis included 2,050,355 veterans with COPD, from which 1,036 were diagnosed with concomitant NTM infection per our inclusion criteria. The age distribution of patients with concurrent COPD and NTM infections is shown in Table [S4](#SM1){ref-type="supplementary-material"}. The majority of these subjects were 75 years old or more at the time of NTM diagnosis (*N* = 280, 27%) followed by the age group of 65--70 years (*N* = 238, 23%). As expected for a veteran population, males numbers comprised the majority of subjects, with only 44 (0.13%) in the NTM group and 33,277 (4.3%) in the non-NTM group being female.

The frequency of comorbidities in the studied population is shown in Table [1](#T1){ref-type="table"}. By univariate analysis, subjects in the NTM group had a significantly higher number of pneumonia diagnosis than subjects in the non-NTM group (23 vs. 14%, respectively, *P* \< 0.001). Although there was no significant difference on the frequency of lung cancer diagnosis between NTM and non-NTM groups (3 vs. 2.7% respectively), lung cancer was found as an independent risk factor for mortality in veterans with COPD (HR = 2.66, CI (2.63--2.69), *P* \< 0.001). Subjects in the NTM group had a significantly higher history of smoking than subjects in the non-NTM group (55.5 vs. 45.2%, respectively, *P* \< 0.001). Both History of pneumonia and smoking tobacco were independently associated with an increased risk of mortality by Cox survival analysis as shown in Table [2](#T2){ref-type="table"}. Obesity was more common among non-NTM subjects (31.4 vs. 19.1%, respectively) and it was found as an independent protective factor for mortality (HR = 0.80, CI (0.79--0.81), *P* \< 0.001). Although the presence of concomitant bronchiectasis was significantly higher in NTM than non-NTM COPD patients (2.5 vs. 0.45%, *P* \< 0.001), it was not found as an independent risk factor for mortality (*P* = 0.869).

###### 

Frequency of comorbidities among COPD veterans with and without NTM infection.

  **Comorbidity**       **NTM (total number: 1,036) *N* (%)**   **Non-NTM (total number: 2,627,108) *N* (%)**   ***P*-value**
  --------------------- --------------------------------------- ----------------------------------------------- ---------------
  Disseminated cancer   9 (0.87%)                               14,185 (1.76%)                                  0.024
  Lung cancer           32 (3.09%)                              22,085 (2.74%)                                  0.504
  ESRD                  11 (1.06%)                              7,810 (0.97%)                                   0.749
  CHF                   113 (10.91%)                            129,471 (16.09%)                                \< 0.001
  Liver disease         53 (5.12%)                              37,702 (4.69%)                                  0.507
  Pneumonia             242 (23.36%)                            111,781 (13.89%)                                \< 0.001
  Aspergillosis         4 (0.39%)                               412 (0.05%)                                     0.002
  AIDS                  39 (3.76%)                              5,330 (0.66%)                                   \< 0.001
  Diabetes Mellitus     251 (24.23%)                            270,189 (33.58%)                                \< 0.001
  CAD                   337 (32.53%)                            326,990 (40.64%)                                \< 0.001
  Psychiatric disease   828 (79.92%)                            600,916 (74.68%)                                \< 0.001
  Tobacco               575 (55.50%)                            363,663 (45.20%)                                \< 0.001
  Immune Disorders      6 (0.58%)                               2,241 (0.28%)                                   0.073
  Cancer                248 (23.94%)                            202,120 (25.12%)                                0.390
  Depression            374 (36.10%)                            271,106 (33.69%)                                0.107
  Atherosclerosis       67 (6.47%)                              55,744 (6.93%)                                  0.624
  Organ transplant      6 (0.58%)                               3,406 (0.42%)                                   0.464
  Cystic fibrosis       1 (0.10%)                               180 (0.02%)                                     0.208
  HTN                   689 (66.51%)                            624,374 (77.60%)                                \< 0.001
  Bronchiectasis        26 (2.51%)                              3,606 (0.45%)                                   \< 0.001
  ILD                   133 (12.84%)                            70,565 (8.77%)                                  \< 0.001
  Pectus excavatum      0 (0.00%)                               115 (0.01%)                                     1.000
  Connective tissue     79 (7.63%)                              38,424 (4.78%)                                  \< 0.001
  Tuberculosis          27 (2.61%)                              3,490 (0.43%)                                   \< 0.001
  GERD                  375 (36.20%)                            311,201 (38.68%)                                0.104
  Asthma                126 (12.16%)                            88,924 (11.05%)                                 0.254
  Obesity               198 (19.11%)                            252,955 (31.44%)                                \< 0.001
  Hyperlipidemia        558 (53.86%)                            553,549 (68.79%)                                \< 0.001

*ESRD, end-stage renal disease; CHF, congestive heart disease; NTM, non-tuberculous mycobacteria; AIDS, acquired immunodeficiency disease; CAD, coronary artery disease; HTN, hypertension; ILD, interstitial lung disease, GERD, gastroesophageal reflux disease, N, number*.

###### 

Comorbidities and hazard ratios of risk factors for mortality in veterans with COPD.

  **Comorbidity**       **Hazard ratio**   **(95% Conf. interval)**   ***p*-value**
  --------------------- ------------------ -------------------------- ---------------
  Disseminated cancer   3.71               3.66--3.75                 \< 0.001
  Lung cancer           2.66               2.63--2.69                 \< 0.001
  ESRD                  2.43               2.39--2.47                 \< 0.001
  CHF                   1.93               1.91--1.94                 \< 0.001
  Liver disease         1.71               1.67--1.73                 \< 0.001
  Pneumonia             1.59               1.58--1.60                 \< 0.001
  Aspergillosis         1.53               1.42--1.65                 \< 0.001
  NTM                   1.43               1.31--1.58                 \< 0.001
  AIDS                  1.25               1.20--1.30                 \< 0.001
  Diabetes mellitus     1.18               1.17--1.19                 \< 0.001
  CAD                   1.17               1.16--1.18                 \< 0.001
  Psychiatric disease   1.16               1.15--1.17                 \< 0.001
  Tobacco               1.16               1.15--1.17                 \< 0.001
  Immune disorders      1.16               1.11--1.21                 \< 0.001
  Cancer                1.12               1.11--1.13                 \< 0.001
  Depression            1.08               1.07--1.09                 \< 0.001
  Atherosclerosis       1.06               1.05--1.07                 \< 0.001
  Organ transplant      1.04               1.00--1.08                 0.043
  Cystic fibrosis       1.04               0.88--1.23                 0.683
  HTN                   1.03               1.02--1.04                 \< 0.001
  Bronchiectasis        0.99               0.97--1.03                 0.869
  ILD                   0.95               0.94--0.96                 \< 0.001
  Pectus excavatum      0.94               0.73--1.21                 0.623
  Connective tissue     0.94               0.93--0.96                 \< 0.001
  Tuberculosis          0.94               0.90--0.98                 \< 0.001
  GERD                  0.86               0.85--0.87                 \< 0.001
  Asthma                0.84               0.83--0.84                 \< 0.001
  Obesity               0.80               0.79--0.81                 \< 0.001
  Hyperlipidemia        0.74               0.73--0.75                 \< 0.001

*ESRD, end-stage renal disease; CHF, congestive heart disease; NTM, non-tuberculous mycobacteria; AIDS, acquired immunodeficiency disease; CAD, coronary artery disease; HTN, hypertension; ILD, interstitial lung disease; GERD, gastroesophageal reflux disease*.

In the Cox regression survival analysis (Table [2](#T2){ref-type="table"}), the highest HR was found in subjects with concurrent metastatic cancer (3.71), followed by lung cancer (2.66), ESRD (2.43), and CHF (1.93). The HR associated with NTM infection was found to be 1.43 (CI (1.31--1.58), *p* \< 0.001).

Discussion {#s4}
==========

While previous studies have evaluated epidemiological data for non-tuberculous mycobacterial infections in the general population, to our knowledge this is the largest epidemiological study performed in a COPD population. The current study found that both the incidence and prevalence rates of NTM infection in veterans with COPD rose over the study period, with a sharp rise in incidence after 2012. We found that NTM infections were associated with 1.43-folds increasing mortality when compared to those that were not infected. It has been shown that Puerto Rico, Florida, and District of Colombia represented the states with the highest period prevalence of NTM among Veterans with COPD in the nation.

The average prevalence rate for NTM infection in our study was \~148.9 patients in 100,000. Compared with the period prevalence rates described by Adjemian et al. for Medicare patients between 1997 and 2007 of 112 cases per 100,000 beneficiaries, veterans with COPD exhibit a significantly higher risk of pulmonary NTM infections ([@B15]). Even after adjustment for a 10-years duration, the period prevalence of pulmonary NTM in COPD was higher than the general population (143.3 patients per 100,000).

Several other studies have been performed to determine the NTM prevalence in high-risk patients. In a study that screened patients with cystic fibrosis (CF) for pulmonary NTM, the overall rate of NTM isolation was 8.1%, representing a point prevalence rate of 4,156 per 100,000 CF patients ([@B16]). In North Carolina, a known hotspot for NTM infections, another study found NTM infection in 19.5% of their patients with CF ([@B17]). Among patients with bronchiectasis, 10% had NTM-positive sputum cultures ([@B18]). These studies are limited by their small sample sizes. Andrejak and her colleagues described the association of NTM infection in subjects with COPD, describing an odd ratio (OR) of 15.7 (95% CI 5.2--11.6) for NTM infection among patients with COPD and a higher OR of 29.1 for COPD patients receiving inhaled corticosteroid therapy ([@B19]). Recent literature has confirmed the association between inhaled corticosteroid use and risk of pulmonary NTM ([@B20]).

Our study is consistent with other recent studies that have demonstrated increased NTM prevalence over time ([@B21], [@B22]). The prevalence rate in 2015 was 198% higher than the prevalence rate in 2001. Interestingly, a similar increase in NTM prevalence was observed over time in patients with cystic fibrosis. Over the 15 years, there was an increase in prevalence rate of 204% ([@B23]). Multiple epidemiologic reports indicate that there has been an increase in NTM prevalence over time ([@B21], [@B22], [@B24]--[@B27]). A 14-country survey evaluating isolations from clinical samples found an increase in the number of NTM isolates over time, particularly for *Mycobactrium avium* complex and *Mycobaceterium xenopi* ([@B25]). A study performed in Canada found an increase in laboratory isolation of NTM from 1997 to 2003, without a change in the fraction of positive cases over time ([@B26]). Domestically, a study conducted with specimens in Oregon also showed an increase in incidence of NTM isolation from 2012 compared to 2007, although this change was not statistically significant ([@B28]). A US-based study evaluated skin sensitization testing for the *Mycobacteria intracellulare* antigen, and showed an increase in prevalence in sensitization from 11.2% in 1972 to 16.6% in 2000, potentially indicating an increase in pulmonary NTM over time ([@B27]).

The trend of incidence of NTM cases over time represents a new phenomenon. While other studies demonstrate a consistently increasing number of incident NTM cases over time, our study found a sharp increase in incidence rate beginning in 2012. This trend applied to both genders and may be explained by increased awareness of this condition along with improved laboratory diagnostic techniques. Throughout the study period, there was no change in the average age of NTM diagnosis. This suggests that the rising incidence after 2012 is not due to earlier diagnosis. One possibility could be the increasing awareness of NTM infections, particularly after development of ATS/IDSA guidelines for NTM in 2007 ([@B29], [@B30]). In addition, extrinsic factors, such as climate change and its associated environmental consequences may increase the risk of COPD, alter the ecology of NTM and affect the dynamics of NTM exposure ([@B31]).

The heat map demonstrates a geographical clustering of NTM infections in southwestern and southeastern United States, with hot spots identified in Southeast Louisiana, Southeast Texas, and around Lake Michigan. This is supported by previous findings that warmer temperatures, lower dissolved oxygen, and lower pH in the soils and waters provide a major environmental source for NTM organisms ([@B32]).

This is the first report, to our best knowledge, discovering Puerto Rico with the highest period prevalence of NTM in the US. We can speculate that the same environmental factors contributing to NTM in Florida could also be involved in Puerto Rico. Another possibility could be a higher exposure to NTM in Puerto Rico. Since the effect of environmental factors on higher rates of NTM in Puerto Rico is not fully understood, we strongly suggest a thorough and detail investigation on NTM in Puerto Rico.

The current study demonstrated that patients with COPD and NTM infection are in significant higher risk of mortality (1.43-folds) compared to those that are not infected. Our data, may be underestimating the true reach of NTM disease and mortality in the general population, as it has been extracted from an overwhelmingly male population. Previous NTM studies show that the number of deaths related to NTM infection is particularly increasing in the female population ([@B33]).

One of the limitations of this study is the disproportionate male population. In their nationwide analysis, Adjemian et al. found that women were 40% more likely to have NTM compared to their male counterparts ([@B15]). Our study indicated an overall incidence rate of 33.1 per 100,000 for males, and 1.1 per 100,000 for females over the entire study period. While we did not observe gender breakdown seen in Adjemian et al. our study population was limited to Veterans. As of 2013, the National Center for Veterans Analysis and Statistics reports that female veterans represent 9.81% of the overall veteran population ([@B34]). While our study demonstrated a progressively increasing proportion of women in incident cases of NTM, by 2015, women still represented only 4% of new NTM cases.

Using administrative data to define cases is another limitation of this study. Ideally, only patients that meet the American Thoracic Society (ATS)/Infectious Disease Society of America\'s (IDSA) pulmonary NTM disease criteria would be coded to have pulmonary NTM. However, it is unclear whether providers would code for pulmonary NTM if patients had only positive sputum cultures. A study in Oregon found that among their patients who were found to have positive NTM cultures, only 56% of them met the ATS/IDSA criteria for pulmonary NTM infection ([@B35]). However, previous studies have indicated that using ICD codes to determine infections from NTM can also miss from 25 to 75% of cases ([@B21]). Recently, authors looked at the accuracy of ICD codes for pulmonary NTM in the VA system, and calculated an accuracy rate as low as 65% ([@B36]). This may indicate an underestimation of true NTM cases, but the change over time may still represent an increase in NTM prevalence.

In conclusion, veterans with COPD have a high risk of NTM infection. There is significant geographic diversity in prevalence and territories with the highest prevalence, such as Puerto Rico should be investigated further. Given the association of NTM infection with a higher risk of death among COPD patients, further strategic actions should be proposed for prevention of NTM infection, with greater awareness and strategies aiming at early detection of disease.
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